NovoCure

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Earnings

Equities

News

Guidance

Health Care

Movers

General

NVCR

NovoCure&#39;s Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio&#39;s expansion.

NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025

Beijing,,China,-,June,4,,2023:,Keysight,Sign,Is,Seen

Markets

Media

Trading Ideas

ADMA

KEYS

On CNBC&#39;s &#34;Mad Money Lightning Round,&#34; Jim Cramer recommended buying Keysight Technologies calling it a &#34;Terrific business.&#34;

Jim Cramer Likes This Tech Stock: &#39;Terrific Business, Niche Business&#39;

Walgreens Boots Alliance Inc.

Mid Cap

NAMS

PDCO

PTVE

STVN

These 10 mid-cap stocks performed well last week. Are they in your portfolio? PDCO, NAMS, WBA, NVCR, RH, PTVE, CRK, RNW, ALK, STVN.

Walgreens Boots Alliance, Alaska Air And RH Are Among Top Mid-Cap Gainers Last Week (December 9-13): Are The Others In Your Portfolio?

NovoCure Ltd

Press Releases

Novocure Appoints Christoph Brackmann as Chief Financial Officer

FDA Approves Novocure's Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure to Participate in Upcoming Investor Conferences

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update

Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference

ZLAB

Artivion

Alphatec Holdings

AtriCure

Axogen

CeriBell

Conmed

Enovis

Paragon 28

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Integra LifeSciences Holdings Corporation - Common Stock

Integra Lifesciences

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Integer Holdings Corporation Common Stock

Integer Holdings

Kestra Medical Technologies, Ltd. - Common Stock

Kestra Medical Techs

LeMaitre Vascular

Masimo

Envista Holdings Corporation Common Stock

Envista Holdings

Omnicell

Pulse Biosciences

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics

QuidelOrtho

Teleflex

TransMedics Group

Tandem Diabetes Care, Inc. - Common Stock

Tandem Diabetes Care

HC Wainwright & Co.

Piper Sandler

Evercore ISI Group

Wells Fargo

JP Morgan

Comments

NovoCure

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga